论文部分内容阅读
目的:观察康艾注射液联合吉西他滨与顺铂方案(GC方案)治疗老年晚期非小细胞肺癌的临床疗效。方法:将60例患者随机分为2组各30例,康艾组予康艾注射液联合GC方案化疗;化疗组只给予GC方案化疗。均化疗4疗程后评价疗效。观察近期疗效、毒副反应、Karnofsky评分及细胞免疫功能指标变化。结果:康艾组近期疗效有效率为33.33%,中位疾病进展时间为5.1月;化疗组近期疗效有效率为30.00%,中位疾病进展时间为4.9月,疗效未见显著性差异(P>0.05);康艾组Ⅲ度粒细胞减少发生率低于化疗组(P<0.05);康艾组Karnofsky评分改善明显(P<0.05);康艾组CD4/CD8及NK阳性细胞率治疗后提高(P<0.05)。结论:康艾注射液有一定的减毒增效作用,其联合GC方案治疗老年晚期非小细胞肺癌粒细胞减少发生率低,可改善患者一般状况及生活质量,提高患者细胞免疫功能。
Objective: To observe the clinical effect of Kangai injection combined with gemcitabine and cisplatin regimen (GC regimen) in the treatment of senile advanced non-small cell lung cancer. Methods: 60 patients were randomly divided into two groups of 30 cases, Kang Yi group Kangai injection combined with GC regimen chemotherapy; chemotherapy group only given GC regimen chemotherapy. After 4 cycles of chemotherapy were evaluated efficacy. To observe the short-term efficacy, toxicity, Karnofsky score and changes in cellular immune function. Results: In the Kangai group, the effective rate was 33.33% in the short term and 5.1 months in the median disease. In the chemotherapy group, the effective rate was 30.00% and the median progression time was 4.9 months. There was no significant difference between the two groups (P> 0.05). The incidence of grade Ⅲ neutropenia in Kangai group was lower than that in chemotherapy group (P <0.05), Karnofsky score in Kangai group was significantly improved (P0.05), and the levels of CD4 / CD8 and NK positive cells in Kangai group were increased (P <0.05). CONCLUSION: Kangai injection has a certain attenuating and synergistic effect. Combined with GC regimen, the incidence of granulocytopenia in elderly advanced non-small cell lung cancer is low, which can improve general condition and quality of life of patients and improve cellular immune function.